Lineage Cell Therapeutics (LCTX) Cash & Equivalents (2010 - 2026)

Lineage Cell Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $45.3 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 5.45% year-over-year to $45.3 million in Q1 2026; TTM through Mar 2026 was $45.3 million, a 5.45% decrease from a year earlier, with the FY2025 full-year figure at $46.0 million, up 12.06% from the prior year.
• Cash & Equivalents retreated to $45.3 million in Q1 2026 per LCTX's latest filing, from $46.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $78.1 million in Q1 2022 and bottomed at $11.4 million in Q4 2022.
• The 5-year median for Cash & Equivalents is $33.9 million (2023), against an average of $38.3 million.
• Across the five-year window, Cash & Equivalents plunged 80.21% in 2023 and jumped 182.03% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $11.4 million in 2022, then soared by 163.63% to $29.9 million in 2023, then soared by 37.02% to $41.0 million in 2024, then grew by 12.06% to $46.0 million in 2025, then fell by 1.5% to $45.3 million in 2026.
• Per Business Quant, the three latest LCTX Cash & Equivalents figures stand at $45.3 million (Q1 2026), $46.0 million (Q4 2025), and $32.2 million (Q3 2025).